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no such recommendation is made for dialysis patients. The
reasoning for this may be that the lack of renal function
would preclude conversion to the active 1,25(OH)2D2,
although there is some evidence that extrarenal sources
can increase 1,25(OH)2D in supplemented anephric
patients.4,5 The data in our study suggest the potential
for a direct suppressive action of 25(OH)D3 on the
parathyroid glands in vivo. Clearly, clinical trials are
necessary to determine the utility of high-dose ergocalci-
ferol supplementation in the control of PTH levels in
dialysis patients.
1. Shahapuni I, Bonne JF, Mailliez S et al. Parathyroid hormone synthesis
suppression by 25(OH)2 vit D3. Kidney Int 2007; (in press).
2. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ. 25-Hydroxyvitamin D3
suppresses PTH synthesis and secretion by cultured bovine parathyroid
cells: potential role for intracrine 1,25-dihydroxyvitamin D3. Kidney Int
2006; 70: 654–659.
3. Vieth R, Ladak Y, Walfish PG. Age-related changes in the
25-hydroxyvitamin D versus parathyroid hormone relationship suggest
a different reason why older adults require more vitamin D. J Clin
Endocrinol Metab 2003; 88: 185–191.
4. Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E. Extra-renal production of
calcitriol in chronic renal failure. Kidney Int 1988; 34: 368–375.
5. Shah N, Bernardini J, Piraino B. Prevalence and correction of 25(OH)
vitamin D deficiency in peritoneal dialysis patients. Perit Dial Int 2005; 25:
362–366.
AJ Brown1 and E Slatopolsky1
1Renal Division, Washington University School of Medicine, St Louis, Missouri,
USA
Correspondence: AJ Brown, Renal Division, Washington University School
of Medicine, St Louis, Missouri, USA. E-mail: abrown@im.wustl.edu
Adynamic bone disease and
malnutrition–inflammation–
cachexia syndrome
Kidney International (2007) 71, 1326; doi:10.1038/sj.ki.5002257
To the Editor: I would like to congratulate Dr Kalantar-
Zadeh and his colleagues on an excellent study concerning
the influence of calcium, phosphate, and parathyroid
hormone (PTH) on dialysis mortality.1
I do, however, have one supplementary question. Most
patients with a low PTH (o150 ng/ml) will have adynamic
bone disease (ABD). The conventional concept of ABD is that
it is an iatrogenic disease caused by oversuppression of PTH
by excessive use of calcium-containing phosphate binders
and active vitamin D. Thus the Kidney Disease Outcomes
Quality Initiative (K/DOQI) guidelines for ABD2 recom-
mend that calcium levels be reduced by reducing the dose of
calcium-based phosphate binders and vitamin D, in order to
stimulate the production of PTH.
From a clinical point of view, this conclusion is puzzling.
Most patients with ABD, as assessed by low PTH, are
characterized by higher age, and a high incidence of
comorbidity, malnutrition, and hypoalbuminemia.3,4 These
are the characteristic hallmarks of malnutrition–inflamma-
tion–cachexia syndrome, MICS (aka malnutrition–inflamma-
tion–atherosclerosis syndrome). These patients will therefore
have a lower requirement for phosphate binders and vitamin
D; indeed, many do not require any therapy at all. There is
therefore an alternative to the ‘iatrogenic’ theory, viz. that
ABD is just a surrogate marker of MICS, and that most of the
increased mortality and comorbidity associated with ABD is
caused by MICS. This has the practical consequence that
‘oversuppression’ of PTH is not as dangerous as implied by
K/DOQI. Support for this position can be found in the recent
study by Block et al.5 where low PTH was a risk factor for
death on an unadjusted analysis, but was associated with
better survival after adjustment for MICS. Furthermore, in a
recent study by Teng et al.6 treatment with vitamin D was
associated with a circa 20% better survival in patients with
low PTH, precisely the group where vitamin D treatment is
supposed to be contraindicated.
Figure 4 in the Kalantar-Zadeh paper lends some support
to this hypothesis, but also suggests that it cannot be the
entire explanation, in that MICS only partly accounted for
the increased mortality of patients with low PTH. One
particular problem that ABD patients may have had in this
study is an increased risk of hypercalcemia due to the lack of
bone buffer function. This should no longer be a problem in
the future due to the introduction of calcium-free phosphate
binders. An analysis was also performed for the effects of
changes in calcium and phosphate in patients starting within
the K/DOQI guidelines for calcium and phosphate (Figure
6). A similar analysis for groups of patients starting with
different levels of PTH could also be performed. The
mortality effects of changes in PTH in these groups, corrected
for (a) case mix, (b) MICS, (c) changes in plasma calcium
and phosphate, (d) combinations, would provide consider-
able support (or the opposite) for the K/DOQI guidelines
concerning PTH.
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